Janetta Trochimiuk - 12 Sep 2026 Form 3 Insider Report for PDS Biotechnology Corp (PDSB)

Reporting relationship
Principal Accounting Officer
Issuer ticker
PDSB
Reported as of
12 Sep 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
18 Sep 2026, 16:34:24 UTC
Prior SEC filing
12 Oct 2021
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
By: /s/ Janetta Trochimiuk

Key filing fact

Janetta Trochimiuk filed Form 3 for PDS Biotechnology Corp (PDSB) on 18 Sep 2026.

Key facts

  • This page summarizes Janetta Trochimiuk's Form 3 filing for PDS Biotechnology Corp (PDSB).
  • 0 reported transactions and 8 derivative rows are listed below.
  • Accepted by SEC: 18 Sep 2026, 16:34.

Change

  • Previous filing in this sequence was filed on 12 Oct 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001807629 Primary reporting owner

Trochimiuk Janetta

Relationship
Principal Accounting Officer
Address
C/O PDS BIOTECHNOLOGY CORP, 303A COLLEGE ROAD EAST, PRINCETON
Signature
By: /s/ Janetta Trochimiuk
Signature date
18 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PDSB holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,124
Date
12 Sep 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PDSB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
70,000
Exercise price
$0.9800
Footnotes
F1
PDSB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$1.79
Footnotes
F2
PDSB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$5.87
Footnotes
F3
PDSB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
25,000
Exercise price
$11.61
Footnotes
F4
PDSB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
31,117
Exercise price
$6.28
Footnotes
F5
PDSB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
27,750
Exercise price
$2.43
Footnotes
F5
PDSB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,000
Exercise price
$1.45
Footnotes
F5
PDSB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
$2.88
Footnotes
F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The option was granted on January 12, 2026, with 25% vesting on January 12, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Footnote F2

The option was granted on June 12, 2025, with 25% vesting on June 12, 2026 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Footnote F3

The option was granted on February 28, 2024, with 25% vesting on February 28, 2025 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Footnote F4

The option was granted on January 4, 2023, with 25% vesting on January 4, 2024 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Footnote F5

The options are fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .